This trial will compare the safety and tolerability of a new antiseptic (IRX-101) vs. standard antiseptic (PI) for eye injections in up to 15 US centers.
1 Primary · 1 Secondary · Reporting Duration: 1-hour post-administration
Awards & Highlights
2 Treatment Groups
1 of 2
1 of 2
240 Total Participants · 2 Treatment Groups
Primary Treatment: IRX-101 · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has the Food & Drug Administration sanctioned IRX-101 for clinical use?
"IRX-101's safety record is highly reliable, and thus it merited a 3 on our team at Power's scale of 1 to 3. This medication has been subject to data collection in multiple trials that suggest efficacy as well as numerous rounds of testing which point towards its security profile." - Anonymous Online Contributor
Is this experiment currently recruiting participants?
"This clinical trial is open for recruitment, with the initial post date having been February 22nd 2023 and a recent edit on March 1st of the same year." - Anonymous Online Contributor
How many research participants are currently engaging in this experiment?
"Indeed, the clinicaltrials.gov page for this study confirms that it is actively enlisting participants. The experiment was first posted on February 22nd 2023 and has been updated as recently as March 1st of the same year. 240 patients are being sought from a single research centre." - Anonymous Online Contributor